FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.991,84 +216,46 (+0,57%) Nasdaq
15.287,19 -314,31 (-2,01%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,20 +0,47 (+0,57%) Bitcoin EUR
60.313,80 +807,27 (+1,36%)
Intellia Therapeutics, Inc. (0JBU.L)
| Chiusura precedente | 21,42 |
| Aperto | 21,28 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 21,02 - 21,57 |
| Intervallo di 52 settimane | 21,02 - 46,91 |
| Volume | |
| Media Volume | 3.135 |
| Capitalizzazione | 10,057M |
| Beta (5 anni mensile) | 1,80 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,06 |
| Prossima data utili | 02 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireIntellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially
- GlobeNewswire
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo
- GlobeNewswire
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedbackPlans to present addi
